文献速递急性肾损伤慢性肾脏病

退伍军人糖尿病肾病患者急性肾损伤后使用SGLT2抑制剂的队列研究

A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
PubMed 文献 · Kidney Int · 2024-04-27

该回顾性队列纳入21,330例2型糖尿病伴蛋白尿的美国退伍军人,旨在评估急性肾损伤(AKI)后使用SGLT2抑制剂(SGLT2i)的时机及处方科室。中位随访2.1年,SGLT2i使用与全因死亡风险降低独立相关(校正HR 0.63,95%CI 0.58-0.68),且无论启动早晚或是否肾功能恢复,获益均稳定。

要点

  • AKI后使用SGLT2i与全因死亡风险降低37%相关(HR 0.63)。
  • 未恢复即启动SGLT2i(HR 0.62)与恢复后启动(HR 0.60)死亡风险均降低。
  • SGLT2i的死亡获益随时间保持稳定(时间交互P=0.19)。

核心结论

  • 在糖尿病肾病退伍军人中,AKI后使用SGLT2i与全因死亡风险降低相关,且无论启动早晚或是否肾功能恢复。

研究设计与样本

  • 回顾性队列研究,纳入21,330例2型糖尿病伴蛋白尿的美国退伍军人,AKI定义为血肌酐升高≥50%。
  • 中位随访2.1年,7,798例死亡(37%),6,562例接受SGLT2i(31%)。

主要发现

  • AKI后使用SGLT2i与较低死亡风险相关(校正HR 0.63,95%CI 0.58-0.68)。
  • 与既未使用SGLT2i也未恢复者相比,仅恢复未用SGLT2i者死亡风险相似(HR 0.97,95%CI 0.91-1.02)。
  • 未恢复即用SGLT2i者死亡风险更低(HR 0.62,95%CI 0.55-0.71),恢复后用SGLT2i者亦更低(HR 0.60,95%CI 0.54-0.67)。
  • SGLT2i效应随时间稳定(时间交互P=0.19)。

临床怎么用

  • 糖尿病肾病患者发生AKI后,可考虑使用SGLT2i以降低死亡风险,无需等待肾功能完全恢复。
  • 启动SGLT2i的时机(早期或晚期)对死亡获益无显著影响。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 研究对象为美国退伍军人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk for several adverse outcomes among patients with diabetic kidney disease. Yet, optimal timing for SGLT2i after acute kidney injury (AKI) is uncertain, as are the providers responsible for post-AKI SGLT2i initiation. Using a retrospective cohort of United States Veterans with diabetes mellitus type 2 and proteinuria, we examined encounters by provider specialty before SGLT2i initiation and subsequent all-cause mortality after hospitalization with AKI, defined by a 50% or more rise in serum creatinine. Covariates included recovery, defined by return to a 110% or less of baseline creatinine, and time since AKI hospitalization. Among 21,330 eligible Veterans, 7,798 died (37%) and 6,562 received a SGLT2i (31%) over median follow-up of 2.1 years. Post-AKI SGLT2i use was associated with lower mortality risk [adjusted hazard ratio 0.63 (95% confidence interval 0.58-0.68)]. Compared with neither SGLT2i use nor recovery, mortality risk was similar with recovery without SGLT2i use [0.97 (0.91-1.02)] but was lower without recovery prior to SGLT2i use [0.62 (0.55-0.71)] and with SGLT2i use after recovery [0.60 (0.54-0.67)]. Finally, the effect of SGLT2i was stable over time (P for time-interaction 0.19). Thus, we observed reduced mortality with SGLT2i use after AKI among Veterans with diabetic kidney disease whether started earlier or later or before or after observed recovery. Hence, patients with diabetic kidney disease who receive a SGLT2i earlier after AKI experience no significant harm impacting mortality and experience a lower mortality risk than those who do not.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Murphy DP, Wolfson J, Reule S, et al. A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease. Kidney Int. 2024. PMID: 38685561. doi:10.1016/j.kint.2024.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。